Cytotoxicity and antibody binding by flow cytometry: A single assay to simultaneously assess two parameters

被引:14
作者
Saw, Chee L. [1 ]
Bray, Robert A. [1 ]
Gebel, Howard M. [1 ]
机构
[1] Emory Univ Hosp, HLA Lab, Dept Pathol, Atlanta, GA 30322 USA
关键词
HLA antibodies; cytotoxicity; flow cytometry; crossmatching; transplant;
D O I
10.1002/cyto.b.20424
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Cell death, as determined by complement-dependent cytotoxicity or antibody binding, as assessed by flow cytometry, are the two main methods histocompatibility laboratories use to identify HLA antibodies. Conventional cytotoxicity assays, even anti-human globulin (AHG) enhanced, are relatively insensitive, subjective and require complement fixation. In contrast, antibody binding assays (e.g.: flow cytometry crossmatch, FCXM) are sensitive, objective, and complement independent. When sera from potential transplant recipients test positive by both methods, most centers would not proceed to transplant unless patients undergo desensitization. However, when the CDC crossmatch is negative but the FCXM positive, how or whether to proceed is controversial. Frequently, both assays are performed. Methods: In this study, we developed a comprehensive procedure that determines cell death, and antibody binding in a single assay: the cytotoxic flow crossmatch (cFCXM). The assay was validated in parallel studies with two other conventional methodologies, namely AHG and FCXM. Results: Using a combination of eight cells and 15 sera, we have determined an optimal method for the simultaneous detection of HLA antibody binding and cytotoxicity using a single platform. Additionally, we have identified three distinct patterns of HLA antibody reactivity: (1) AHG(pos)/cFCXM(pos)/FCXMpos, (2) AHG(neg)/cFCXM(neg)/FCXMpos, and (3) a previously unrecognized category, namely, AHG(neg)/cFCXM(pos)/ FCXMpos. Conclusions: These studies document that cytotoxicity and antibody binding can be simultaneously assessed and marks the first demonstration of complement-dependent HLA antibodies undetectable by conventional cytotoxicity. Routine application of this assay may provide new insights regarding transplantation of patients presenting as AHG(neg)/FCXMpos by classifying them according to their cFCXM status. (C) 2008 Clinical Cytometry Society.
引用
收藏
页码:287 / 294
页数:8
相关论文
共 19 条
[1]  
*AM SOC HIST IMM, 1998, STAND HIST TEST
[2]   Transplanting the highly sensitized patient: The emory algorithm [J].
Bray, R. A. ;
Nolen, J. D. L. ;
Larsen, C. ;
Pearson, T. ;
Newell, K. A. ;
Kokko, K. ;
Guasch, A. ;
Tso, P. ;
Mendel, J. B. ;
Gebel, H. M. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2006, 6 (10) :2307-2315
[3]   Evolution of HLA antibody detection - Technology emulating biology [J].
Bray, RA ;
Nickerson, PW ;
Kerman, RH ;
Gebel, HM .
IMMUNOLOGIC RESEARCH, 2004, 29 (1-3) :41-53
[4]   THE FLOW CYTOMETRIC CROSSMATCH - DUAL-COLOR ANALYSIS OF T-CELL AND B-CELL REACTIVITIES [J].
BRAY, RA ;
LEBECK, LK ;
GEBEL, HM .
TRANSPLANTATION, 1989, 48 (05) :834-840
[5]   Successful renal transplantation despite low levels of donor-specific HLA class I antibody without IVIg or plasmapheresis [J].
Bryan, Christopher F. ;
McDonald, Scott B. ;
Luger, Alan M. ;
Shield, Charles F. ;
Winklhofer, Franz T. ;
Borkon, A. Michael ;
Warady, Bradley A. ;
Aeder, Mark I. ;
Murillo, Daniel .
CLINICAL TRANSPLANTATION, 2006, 20 (05) :563-570
[6]   ANTIGENIC SPECIFICITY OF ANTIBODY REACTIVE IN THE ANTIGLOBULIN-AUGMENTED LYMPHOCYTOTOXICITY TEST [J].
FULLER, TC ;
PHELAN, D ;
GEBEL, HM ;
RODEY, GE .
TRANSPLANTATION, 1982, 34 (01) :24-29
[7]   Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: Contraindication vs. risk [J].
Gebel, HM ;
Bray, RA ;
Nickerson, P .
AMERICAN JOURNAL OF TRANSPLANTATION, 2003, 3 (12) :1488-1500
[8]   Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation [J].
Gloor, JM ;
DeGoey, S ;
Ploeger, N ;
Gebel, H ;
Bray, R ;
Moore, SB ;
Dean, PG ;
Stegall, MD .
TRANSPLANTATION, 2004, 78 (02) :221-227
[9]   IMPROVED GRAFT-SURVIVAL FOR FLOW-CYTOMETRY AND ANTIHUMAN GLOBULIN CROSSMATCH-NEGATIVE RETRANSPLANT RECIPIENTS [J].
KERMAN, RH ;
VANBUREN, CT ;
LEWIS, RM ;
DEVERA, V ;
BAGHDAHSARIAN, V ;
GEROLAMI, K ;
KAHAN, BD .
TRANSPLANTATION, 1990, 49 (01) :52-56
[10]   HLA-DR TYPING BY PCR AMPLIFICATION WITH SEQUENCE-SPECIFIC PRIMERS (PCR-SSP) IN 2 HOURS - AN ALTERNATIVE TO SEROLOGICAL DR TYPING IN CLINICAL-PRACTICE INCLUDING DONOR-RECIPIENT MATCHING IN CADAVERIC TRANSPLANTATION [J].
OLERUP, O ;
ZETTERQUIST, H .
TISSUE ANTIGENS, 1992, 39 (05) :225-235